Relative to existing gene signatures, the STRESS signature better predicted not only whether cells would later develop into ...

Learn more about the research of Mayo Clinic's Gene Editing and Cellular Engineering Laboratory led by David (Chun-Wei) D.

Biopharma dealmaking in June 2025 reached $35.07 billion, the highest monthly total of the year so far and one of the strongest single-month performances in recent years. The June surge helped push ...

At first blush, the brain’s extracellular matrix (ECM) seems like the opposite of synaptic plasticity. Plasticity is the ability to change; the ECM is stable, to the point that it is often described ...

In this work, the researchers showed how water molecules near a protein surface can influence misfolding. A mutation that is related to tauopathies has a subtle effect on water's dynamic structure in ...

PMR-116 shows promise in treating MYC-driven cancers, offering hope for patients with aggressive tumors in upcoming human trials.

A new study uncovers a surprising mechanism by which the SARS-CoV-2 virus, responsible for COVID-19, might cause immune-mediated tissue damage by targeting cells it has never infected.

The MYC protein is a well-established driver in up to 70% of human cancers, but has long been considered “undruggable” due to the absence of suitable binding pockets for high-affinity small ...

Extending this discovery recently in Cell, Flynn and colleagues showed that glycoRNAs form highly organized clusters with RNA-binding proteins on the cell surface.

Scientists identified Myc in the 1970s, and they discovered the protein does not have to be mutated to become cancerous. Instead, it’s the continuous production that makes the protein dangerous.

Scientists suggest understanding ecDNA’s role in pancreatic cancer could potentially guide future strategies for making tumors more vulnerable to treatment.